Acadian Asset Management
CTIC

Acadian Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Acadian Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,524
Closed -$19K – 2419
2020
Q1 		$19K Buy
+20,524
New +$23.5K ﹤0.01% 1660
2017
Q2 		– Sell
-43,044
Closed -$181K – 1760
2017
Q1 		$181K Buy
+43,044
New +$199K ﹤0.01% 1056
2016
Q4 		– Sell
-2,161
Closed -$8K – 1876
2016
Q3 		$8K Buy
+2,161
New +$7.87K ﹤0.01% 1269

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Acadian Asset Management's CTIC Position: Q2 2020 in Review

Acadian Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2020, closing a stake of 20,524 shares — an estimated $19K sold.

Acadian Asset Management first reported a position in CTIC in Q3 2016 and held it in 3 quarters. The position peaked at $181K in Q1 2017. 43 funds tracked by Wall St. Rank hold CTIC as of Q2 2020.

  • Acadian Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2020 after selling out during the quarter.
  • Acadian Asset Management sold 20,524 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2020, an estimated $19K.
  • Acadian Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2016 and held it in 3 quarters.
  • Acadian Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $181K in Q1 2017.
  • 43 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2020.

Based on Acadian Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.